Evaluating and treating cardiometabolic risk factors: a case discussion

Pharmacotherapy
Stuart T HainesSuzanne K Sysko

Abstract

Reducing the risk for coronary heart disease (CHD) requires a comprehensive assessment of cardiometabolic risk factors along with the initiation of nonpharmacologic and pharmacologic therapies to mitigate these risk factors. A case study is presented to illustrate the approach to evaluating a patient and selecting among available and emerging therapeutic modalities to reduce CHD risk.

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Oct 26, 2001·JAMA : the Journal of the American Medical Association·S YusufUNKNOWN HOPE Study Investigators
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Dec 31, 2002·Journal of the American College of Cardiology·Michael H DavidsonEnrico P Veltri
Mar 14, 2003·The American Journal of Cardiology·Harold E BaysUNKNOWN ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Steven E NissenRichard Kerensky
Nov 25, 2003·Diabetes Care·Alam KhanRichard A Anderson
Apr 6, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Martin C MichelUwe Heemann
Apr 9, 2004·The New England Journal of Medicine·Margaret E BrousseauDaniel J Rader
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Oct 27, 2004·Archives of Internal Medicine·Elaine ChiquetteRalph Defronzo
Nov 5, 2004·Molecular and Cellular Biochemistry·Darren J Holub, Bruce J Holub
Dec 25, 2004·Diabetes Care·UNKNOWN American Diabetes Association
Jan 29, 2005·Diabetes Care·Sachiko HonjoHiroyuki Koshiyama
Mar 10, 2005·The Annals of Pharmacotherapy·Steven Thomas Boyd, Brad Allen Fremming
Mar 29, 2005·Diabetes Care·Robert RatnerUNKNOWN Diabetes Prevention Program Research Group
Oct 22, 2005·JAMA : the Journal of the American Medical Association·Steven E NissenEric J Topol
Nov 18, 2005·The New England Journal of Medicine·Jean-Pierre DesprésUNKNOWN Rimonabant in Obesity-Lipids Study Group
Dec 24, 2005·Diabetes Care·UNKNOWN American Diabetes Association
Feb 16, 2006·JAMA : the Journal of the American Medical Association·F Xavier Pi-SunyerUNKNOWN RIO-North America Study Group
Aug 1, 2004·Molecular and Cellular Biochemistry·Darren J Holub, Bruce J Holub

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Related Papers

Menopause : the Journal of the North American Menopause Society
Francine K Welty
Clinics in Podiatric Medicine and Surgery
R J Roche, W B Forman
International Journal of Obesity : Journal of the International Association for the Study of Obesity
H GhandehariN D Wong
Hematology/oncology Clinics of North America
Mordecai Potash, William Breitbart
The American Journal of the Medical Sciences
Carl J LavieJames H O'Keefe
© 2022 Meta ULC. All rights reserved